Pharmacological targeted therapy of Braf mutant melanoma (Braf and MEK inhibitors)

Abstract

The Thesis is based upon the approach of Pharmacological targeted therapy of Braf mutant melanoma with both Braf and MEK inhibitors. The BRAF inhibitors, Vemurafenib (Zelboraf) and Dabrafenib (Tafinlar), targets the BRAF kinase directly resulting in the cease of cell growth, while MEK inhibitors, such as Trametinib (Mekinist) and Cobimetinib (Cotellic), rather than targeting the BRAF kinase it acts on MEK kinase given as a pill, to be taken once daily. The efficiency of MEK inhibitor compared to BRAF inhibitors is less and a better approach is to combine MEK inhibitors with BRAF inhibitors. This shows a high efficacy and proves to act on tumors for longer periods.